Funded by the European Union

UNDINE	
Project number:	101057100
Project name:	The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalised medicine
Topic:	HORIZON-HLTH-2021-DISEASE-04-07
Type of action:	HORIZON Research and Innovation Actions (RIA)
Starting date of action:	1 June 2022
Project duration:	48 months
Project end date:	31 May 2026
Deliverable number:	D4.8
Deliverable title:	Summary of dissemination activities for the project in relation to work package 4
Document version:	Ver1.0
WP number:	WP4
Lead beneficiary:	AU, INSERM
Main author(s):	Trine Mogensen (AU), Jean-Laurent Casanova (INSERM), Giuseppe Novelli (UNITOV)
Internal reviewers:	Laurent Abel (INSERM), André Walter (AU)
Nature of deliverable:	DEC
Dissemination level:	PU
Delivery date from Annex 1:	M48
Actual delivery date:	M48

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.

Executive Summary

This deliverable summarizes the dissemination activities for WP4 over the course of the project time classified according to the target: For the general public and patients, we listed the oral and written. For the scientific and medical community, we reported the academics courses and meeting participations related to the UNDINE project. We also provided an overview of the publication efforts with open access.

Abbreviations

D	Deliverable
EC	European Commission
WP	Work Package
WT	Work Task

Contents

1 Dissemination activities to reach the general public and patients

Social media and online communication:

- Twitter/X account @casanova_lab (PI) relays all information about UNDINE & the advancement of the project
- On the new website on Human Genetics of Infectious Diseases laboratory, we inform about UNDINE project (https://www.hgid.org/collaborative-efforts/), and we include a link to UNDINE-homepage
- On the UNDINE-homepage, we inform about UNDINE project, including recent outreach and dissemination activities (https://www.undine.au.dk).

Written communications:

French Institutional Press Offices (Inserm and Institut Imagine) regularly release updates on the progress of UNDINE related projects, aimed at the general public:

- 10/02/2022 Aarhus University News reports about the new UNDINE project: "Major grant: Aarhus helping to answer the big coronavirus questions" (https://health.au.dk/en/display/artikel/millionbevilling-aarhus-skal-vaere-med-til-at-besvare-de-store-corona-spoergsmaal)
- 15/06/2022 https://presse.inserm.fr/covid-19-un-deficit-immunologique-expliquerait-pres-dun-quart-des-tres-rares-formes-severes-observees-chez-les-vaccines/45433/
- 09/09/2022 https://www.aphp.fr/contenu/dilemme-cytokinique-virus-contre-inflammation
- 17/01/2023 https://u-paris.fr/covid-19-des-defauts-genetiques-responsables-du-syndrome-inflammatoire-multi-systemique-de-lenfant/
- 17/01/2023 https://www.aphp.fr/contenu/covid-19-des-defauts-genetiques-responsables-du-syndrome-inflammatoire-multi-systemique-de
- 18/01/2023 https://presse.inserm.fr/covid-19-des-defauts-genetiques-responsables-du-syndrome-inflammatoire-multi-systemique-de-lenfant/46337/
- 26/07/2023 https://www.institutimagine.org/fr/les-auto-anticorps-contre-les-interferons-ou-pourquoi-certains-virus-nous-affectent-differemment
- 05/12/2023 https://www.institutimagine.org/fr/un-nouveau-groupe-de-maladies-genetiques-explique-la-production-dautoanticorps-contre-les-1623
- 06/12/2023 https://u-paris.fr/un-nouveau-groupe-de-maladies-genetiques-expliquent-la-predisposition-a-des-maladies-virales-severes/
- 06/12/2023 https://www.aphp.fr/contenu/un-nouveau-groupe-de-maladies-genetiques-expliquent-la-predisposition-des-maladies-virales
- 05/01/2024 https://www.institutimagine.org/fr/les-auto-anticorps-anti-ifn-de-type-i-detectes-et-operants-des-lenfance-1635

Interviews and press releases in various media:

- 17/11/2023 Trine Mogensen reported in an article for the Danish newspaper 'Berlingske' about the importance of the current COVID-19 research, highlighting the focus on the immense differences in individual susceptibilities to the disease. Prof. Mogensen emphasised the importance an understanding of the risk factors that predict a severe progression of an infection (https://www.berlingske.dk/samfund/ny-forskning-derfor-har-en-raekke-boern-og-unge-oeget-risiko-for-at-doe-af)
- Nov 2023 Trine Mogensen reported to the Danish parliament. She presented the objectives, results, and visions of UNDINE and also discussed different European strategies for 1) susceptible individuals offered COVID-19 vaccination and 2) public health strategies for examination and management of individuals with Long-COVID-19.

Public lectures:

- Trine Mogensen gave a lecture for Folkeuniversitetet (Danish community college) with the topic: “The immune system and how it works and fights viral infections”, March 5th, 2024.
- Trine Mogensen gave a lecture to a lay audience at the community college in Aarhus/Denmark in January 2026. It was tailored for the general public interested in medical topics as part of a series of talks called: “Medicine in one semester”. Trine gave a seminar with the title “Immunology – How does the body defend itself?”. The work of UNDINE was a substantial part of the lecture, communicating the results of the project to the public.
- Postdoc from Trine Mogensen’s lab presented the UNDINE project in a talk for the public entitled: “Genetics and the immune system determines severity of coronavirus infections and postinfectious disorders” at the ‘Pint of science’ festival in Aarhus, DK, May 18-20th, 2026.

2 Dissemination activities to reach the scientific and medical community

Overview of conferences in which Immunological and genetic bases of COVID-19 were presented:

2022:

1. Jean-Laurent Casanova. 17th Annual Symposium on Primary Immunodeficiency Diseases, Foundation for Primary Immunodeficiency Diseases, Newport Beach, CA, USA, November 2022
2. Jean-Laurent Casanova. Plenary Lecture, Joint Congress: International Immunocompromised Host Society 22nd Symposium, Annual Congress Swiss Society for Allergology and Immunology (H Hirsch, M Recher), Congress Center Basel, Switzerland, September 2022
3. Jean-Laurent Casanova. Philip I. Marcus Memorial Lecture, Philip I. Marcus Symposium: Interferons and antiviral immunity, Cytokines 2022 (Mary Ann Liebert, Inc. Publishers), Big Island, HI, USA (virtual), September 2022

2023:

4. Jean-Laurent Casanova. 30th Annual Meeting of the Henry Kunkel Society: Innate Immunity: From Basic Biology to Human Disease, The Rockefeller University, New York, NY, USA, April 2023
5. Jean-Laurent Casanova. 2nd International Symposium on Inborn Errors of Immunity in the Northern Atlantic, Tórshavn, Faroe Islands, June 2023
6. Jean-Laurent Casanova. 18th Annual Symposium on Primary Immunodeficiency Diseases (S Gupta, JL Casanova), Foundation for Primary Immunodeficiency Diseases, Newport Beach, CA, USA, November 2023
7. Jean-Laurent Casanova. Distinguished Lectures in Genetics Seminar Series, Division of Human Genetics, Cincinnati Children’s Hospital (S Waggoner), Cincinnati, OH, USA, February 2023
8. Jean-Laurent Casanova. Distinguished Seminar (K Hisert), National Jewish Health, Denver, CO, USA, March 2023
9. Jean-Laurent Casanova. Inaugural Speaker, Robert W. Finberg, MD Memorial Lecutre: Pandemics, Plagues and Viruses (K Fitzgerald, D Golenbock), University of Massachusetts Chan Medical School, Worcester, MA, USA, March 2023
10. Jean-Laurent Casanova. Distinguished Faculty Lectureship in Infectious Diseases (J Coburn), Medical College of Wisconsin, Milwaukee, WI, USA, April 2023

11. Jean-Laurent Casanova. Sidney Leskowitz Memorial Lecture (A Poltorak), Tufts University Medical School, Boston, MA, USA, April 2023
12. Jean-Laurent Casanova. Founders Lecture, Latin American Society for Immunodeficiencies (LASID) 2023 Meeting (G Segundo, A Alvarez), Mexico City, Mexico, October 2023
13. Giuseppe Novelli. Difetti congeniti dell'immunità e determinanti comuni dell'infezione virale. Meeting on respiratory viruses in post-pandemic times, Lecce, Italy, December 2023

2024:

14. Jean-Laurent Casanova. Keynote Lecture, 2nd Fenglin International Clinical Immunology Forum (X Wang, JL Casanova), Children's Hospital of Fudan University, Shanghai, China, March 2024
15. Jean-Laurent Casanova. Keynote Lecture, 2024 Formasa Translational Immunology Symposium (CL Ku, MD Kuo), Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, March 2024
16. Jean-Laurent Casanova. 2nd Fenglin International Clinical Immunology Forum (X Wang, JL Casanova), Children's Hospital of Fudan University, Shanghai, China, March 2024
17. Jean-Laurent Casanova. 31th Annual Meeting of the Henry Kunkel Society: Innate Immunity: From Basic Biology to Human Disease, The Rockefeller University, New York, NY, USA, April 2024
18. Giuseppe Novelli. Immunological and Genetic Predisposition To Infectious Diseases, Human Genome Meeting. (HUGO) 2024, Rome, Italy, April 2024

2025:

19. Giuseppe Novelli. Modelling severe Covid-19 in TLR3-mutated hiPSCS-derived lung-organoids. the Human Genome Meeting (HGM) in Durban / South Africa, April 11th-14th 2025

2026:

20. Giuseppe Novelli. Transforming lives through diagnosis: The role of the geneticist in rare disease care. International Conference on Rare Diseases in Tirana / Albania, February 20th, 2026
21. Trine Mogensen. When the immune system fails: new answers to old infectious diseases, Meeting of the Danish Society of Infectious Diseases, Aarhus, DK, April 2026

Awards:

- Award of the 2025 Novo Nordisk Prize to Jean-Laurent Casanova (INSERM). He gave a lecture at the award ceremony in Copenhagen / Denmark in April 2025. He talked about how for decades, scientists believed that infections were determined solely by viruses and bacteria, and how his research has revealed a more complex reality: that genes play a fundamental role in determining who gets seriously ill and who stays healthy, a pivotal point of investigations conducted in the UNDINE-project and in WP4 in particular.

Overview of UNDINE's publication efforts with open access

1. Casanova JL, Abel L. From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell. 2022. 185: 3086-103
2. Lee D, et al. Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children. Science. 2023. 379(6632):eabo3627.

3. Mathian A, et al. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. Ann Rheum Dis 2022. 81: 1695-703
4. Matuozzo D, et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Med. 2023;15(1):22.
5. Zhang Q, et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med 2022. 219
6. Zhang Q, et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med. 2022. 219(11):e20220514.
7. Sokal A, et al. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. J Exp Med. 2023. 220(1):e20220258.
8. Cobat A, et al. Human Genomics of COVID-19 Pneumonia: Contributions of Rare and Common Variants. Annu Rev Biomed Data Sci. 2023. 6:465-486.
9. Philippot Q, et al. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia. J Clin Immunol. 2023. 43(6):1093-1103.
10. Bucciol G, et al. Human inherited complete STAT2 deficiency underlies inflammatory viral diseases. J Clin Invest. 2023. 133(12):e168321.
11. Bastard P, et al. Human autoantibodies neutralizing type I IFNs: From 1981 to 2023. Immunol Rev. 2024. 3 22(1):98-112.
12. Bastard P, et al. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children. J Exp Med. 2024. 221(2):e20231353.
13. Biancolella M, Colona VL, Luzzatto L, ... Novelli G, Reichardt JKV.COVID-19 annual update: a narrative review Hum Genomics. 2023 Jul 24;17(1):68.
14. Latini A, De Benedittis G, Colafrancesco S, ... Novelli G, ... Borgiani P. PCSK3 Overexpression in Sjögren's Syndrome Patients May Be Regulated by rs4932178 SNP in Its Promoter Region and Correlates with IFN-γ Gene Expression. Genes (Basel). 2023 Apr 26;14(5):981.
15. Vanker M, Särekannu K, Fekkar A, ... Zhang SY, Mogensen TH, ... Casanova JL, Kisand K. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia. J Interferon Cytokine Res. 2023 May 29.
16. Su HC, Jing H, Zhang Y, Casanova JL. Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia. Annu Rev Immunol. 2023; 41:561-585.
17. Aquino Y, Bisiaux A, Li Z, ... Abel L, Casanova JL, V ... Quintana-Murci L. Dissecting human population variation in single-cell responses to SARS-CoV-2. Nature. 2023 Aug 9.
18. Philippot Q, Fekkar A, Gervais A ... Casanova JL, Puel A. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia. J Clin Immunol. 2023 May; 20:1–11.
19. Garcia-Carcia A, Perez-DeDiego R, Flores C, ... Meyts I, ... Casanova J-L, ... et al. Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia. Exp Med. 2023 May 1; 220(5):e20220170.
20. Heterozygous BTNL8 variants in individuals with multisystem inflammatory syndrome in children (MIS-C). Bellos E, Santillo D, Vantourout P, … Pérez de Diego R, … Abel L, Zhang SY, Casanova JL, … Sancho-Shimizu V. J Exp Med. 2024 Dec 2;221(12):e20240699. doi: 10.1084/jem.20240699. Epub 2024 Nov 22. PMID: 39576310.
21. Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease. Gervais A, Bastard P, Bizien L, … Abel L, … Zhang SY, Casanova JL. J Exp Med. 2024 Dec 2;221(12):e20240942. doi: 10.1084/jem.20240942. Epub 2024 Nov 1. PMID: 39485284.
22. The Microbe, the Infection Enigma, and the Host. Casanova JL, Abel L. Annu Rev Microbiol. 2024 Nov;78(1):103-124. doi: 10.1146/annurev-micro-092123-022855. Epub 2024 Nov 7. PMID: 38986133.
23. IL-7-dependent and -independent lineages of IL-7R-dependent human T cells. Arango-Franco CA, Ogishi M, Unger S, … Casanova JL, Puel A. J Clin Invest. 2024 Oct 1;134(19):e180251. doi: 10.1172/JCI180251. PMID: 39352394.

24. Inherited human RelB deficiency impairs innate and adaptive immunity to infection. Le Voyer T, Maglorius Renkilaraj MRL, Moriya K, … Abel L, … Casanova JL, … Puel A. Proc Natl Acad Sci U S A. 2024 Sep 10;121(37):e2321794121. doi: 10.1073/pnas.2321794121. Epub 2024 Sep 4. PMID: 39231201.
25. SARS-CoV-2 brainstem encephalitis in human inherited DBR1 deficiency. Chan YH, Lundberg V, Le Pen J, … Abel L, Mogensen TH, … Casanova JL, … Zhang SY. J Exp Med. 2024 Sep 2;221(9):e20231725. doi: 10.1084/jem.20231725. Epub 2024 Jul 18. PMID: 39023559.
26. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection. Marchal A, Cirulli ET, Neveux I, … Spaan AN, … Zhang SY, … Fellay J, … Sancho-Shimizu V, Abel L, Casanova JL, … Bolze A. HGG Adv. 2024 Jul 18;5(3):100300. doi: 10.1016/j.xhgg.2024.100300. Epub 2024 Apr 26. PMID: 38678364.
27. Human determinants of age-dependent patterns of death from infection. Abel L, Casanova JL. Immunity. 2024 Jul 9;57(7):1457-1465. doi: 10.1016/j.immuni.2024.05.020. PMID: 38986441.
28. Human life within a narrow range: The lethal ups and downs of type I interferons. Crow YJ, Casanova JL. Sci Immunol. 2024 Jul 5;9(97):eadm8185. doi: 10.1126/sciimmunol.adm8185. Epub 2024 Jul 5. PMID: 38968338.
29. A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern. Murdocca M, Romeo I, Citro G, ... Novelli G. Pharmaceuticals (Basel). 2024 Jul 4;17(7):891. doi: 10.3390/ph17070891. PMID: 39065742.
30. Variation of the 3'RR1 HS1.2 Enhancer and Its Genomic Context. Jodice C, Malaspina P, Ciminelli BM, … Novelli G, Novelletto A. Genes (Basel). 2024 Jun 29;15(7):856. doi: 10.3390/genes15070856. PMID: 39062635.
31. The ouroboros of autoimmunity. Casanova JL, Peel J, Donadieu J, … Bastard P. Nat Immunol. 2024 May;25(5):743-754. doi: 10.1038/s41590-024-01815-y. Epub 2024 May 2. PMID: 38698239.
32. Human autoantibodies neutralizing type I IFNs: From 1981 to 2023. Bastard P, Gervais A, Le Voyer T, … Abel L, Zhang SY, … Casanova JL. Immunol Rev. 2024 Mar;322(1):98-112. doi: 10.1111/imr.13304. Epub 2024 Jan 9. PMID: 38193358.
33. The immunopathological landscape of human pre-TCRα deficiency: From rare to common variants. Materna M, Delmonte OM, Bosticardo M, … Bastard P, … Meyts I, … Abel L, … Casanova JL, Béziat V. Science. 2024 Mar;383(6686):eadh4059. doi: 10.1126/science.adh4059. Epub 2024 Mar 1. PMID: 38422122.
34. The “Black Swan Principle” and the Genetics of Complex Diseases. Novelli G, Reichardt JKV. Top Italian Scientists Journal; 2024;1(1).https://doi.org/10.62684/YEWJ9912.
35. Characterization of the symmetrical benzimidazole twin drug TL1228: the role as viral entry inhibitor for fighting COVID-19. Murdocca M, Andrade Santos-Filho O, ... Novelli G. Biol Direct. 2024 Oct 16;19(1):93. doi: 10.1186/s13062-024-00523-9. PMID: 39415197.
36. A sensitive assay for measuring whole-blood responses to type I IFNs. Gervais A, Le Floc'h C, Le Voyer T, ... Zhang SY, ... Bastard P, Casanova JL. Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2402983121. doi: 10.1073/pnas.2402983121. Epub 2024 Sep 23. PMID: 39312669.
37. A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern. Murdocca M, Romeo I, Citro G, ... Novelli G. Pharmaceuticals (Basel). 2024 Jul 4;17(7):891. doi: 10.3390/ph17070891. PMID: 39065742.
38. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children. Bastard P, Gervais A, Taniguchi M,... Meyts I, ... Pujol A, ... Zhang SY, ... Mogensen TH, ... Soler-Palacin P, ... Brodin P, Abel L, ... Kisand K, ... Casanova JL. Exp Med. 2024 Feb 5;221(2):e20231353. doi: 10.1084/jem.20231353. Epub 2024 Jan 4. PMID: 38175961.

39. Modelling severe COVID-19 in TLR3-mutated hiPSCs-derived lung organoids. Latini A, Spitalieri P, Centofanti F, … Novelli G. Cell Death Discov. 2025 Dec 26. doi: 10.1038/s41420-025-02936-5. Epub ahead of print. PMID: 41453867.
40. Deleterious variants in the autophagy-related gene RB1CC1/FIP200 impair immunity to SARS-CoV-2. Hu L, van der Sluis RM, Castelino KB, …Casanova JL …Mogensen TH. Nat Commun. 2025 Nov 27;16(1):10618. doi: 10.1038/s41467-025-65308-8. PMID: 41309545.
41. Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases. Rosain J, Le Voyer T, Liu X, … Bastard P, … Casanova JL. J Exp Med. 2024 Nov 4;221(11):e20231152. doi: 10.1084/jem.20231152. Epub 2024 Oct 1. PMID: 39352576.
42. The seven enigmas of SARS-CoV-2: from the past to the future. Andreakos E, Arkin L, Bastard P, Bolze A, Borghesi A, Brodin P, Casanova JL, Casari G, Cobat A, Drolet B, Fellay J, Hsieh E, Meyts I, Mogensen TH, Sancho-Shimizu V, Spaan AN, … Zhang SY; COVID Human Genetic Effort+. J Hum Immun. 2025 Nov 3;1(4):e20250149. doi: 10.70962/jhi.20250149. Epub 2025 Oct 24. PMID: 41347066.
43. Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains. Saidoune F, … Fellay J, Casanova JL, … Yatim A. J Exp Med. 2025 Jul 7;222(7):e20231467. doi: 10.1084/jem.20231467. Epub 2025 Apr 14. PMID: 40227192.
44. Rapid Detection of Anti-IFN-α2 Autoantibodies Using a New Automated VIDAS Assay Prototype. Pons S, Generenaz L, Gervais A, ... Bastard P, ... Casanova JL, Fleurie A, Trouillet-Assant S. Eur J Immunol. 2025 Apr;55(4):e202451516. doi: 10.1002/eji.202451516. PMID: 40223598.
45. Genetic Landscape and Mitochondrial Metabolic Dysregulation in Patients Suffering From Severe Long COVID. Hansen KS, Jørgensen SE, Cömert C, ... Mogensen TH. J Med Virol. 2025 Mar;97(3):e70275. doi: 10.1002/jmv.70275. PMID: 40025839.
46. Severe West Nile Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Infections in a Patient With Thymoma and Anti-Type I Interferon Antibodies. Barzaghi F, Visconti C, Pipitone GB, ... Bastard P, ... Casanova JL, ... Casari G, Aiuti A. J Infect Dis. 2025 Feb 4;231(1):e206-e212. doi: 10.1093/infdis/jiae321. PMID: 38976510.
47. A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunit. Al Qureshah F, Le Pen J, ... Abel L, Bastard P, ... Zhang SY, ... Casanova JL, Zhang Q. J Exp Med. 2025 Feb 3;222(2):e20241413. doi: 10.1084/jem.20241413. PMID: 39680367.
48. Genetic diversity of the immunoglobulin heavy chain locus in cohorts of patients affected with SARS-CoV-2. Malaspina P, Jodice C, Ciminelli BM, ... Novelli G, Novelletto A. Hum Genomics. 2025 Jan 30;19(1):7. doi: 10.1186/s40246-025-00719-8. PMID: 39885568.
49. Defective RNA Polymerase III sensing of mitochondrial DNA in pulmonary epithelial cells impairs type I IFN immunity to SARS-CoV-2. Møhlenberg M, Jørgensen SE, Marije van der Sluis R, Zillinger T, Hinke DM, … Pérez de Diego R, Pujol A, Zhang SY, … Abel L, Cobat A, Casanova JL, Mogensen TH. Proc Natl Acad Sci U S A. 2026 Mar 24;123(12):e2522111123. doi: 10.1073/pnas.2522111123. Epub 2026 Mar 16. PMID: 41838921.
50. Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis. Gervais A, Marchal A, Boucherit S, … Mogensen TH, Bastard P, … Casanova JL, Jouanguy E. J Exp Med. 2026 Mar 2;223(3):e20251760. doi: 10.1084/jem.20251760. Epub 2025 Dec 5. PMID: 41348319.
51. Autoantibodies neutralizing type I IFNs in a fatal case of H5N1 avian influenza. Zhang Q, Conrad TS, Moncada-Velez M, … Bastard P, … Casanova JL. J Exp Med. 2026 Mar 2;223(3):e20251962. doi: 10.1084/jem.20251962. Epub 2025 Dec 5. PMID: 41348320.
52. Shared TCR Vβ21.3+ T cell immunological signature between MIS-A and MIS-C. Khoryati L, Sørensen SB, Parizot C, … Mogensen TH, Belot A. J Hum Immun. 2026 Jan 8;2(2):e20250050. doi: 10.70962/jhi.20250050. PMID: 41646957.